Seems you have not registered as a member of localhost.saystem.shop!
You may have to register before you can download all our books and magazines, click the sign up button below to create a free account.
Personalized Therapy for Multiple Myeloma
This book provides the clinician with concise, practical guidance on risk stratification and therapeutic decision making in patients with multiple myeloma. In addition, the available clinical trial and research data are summarized into meaningful reviews and evidence-based recommendations for treatment are presented. The coverage encompasses all phases and forms of disease, including high-risk myeloma. Over recent decades, greater understanding of the biology of myeloma has fostered the development of new, more effective drugs, leading to remarkable improvements in survival. To continue this momentum, several recent prospective trials have aimed to identify further potential therapeutic targets or to evaluate various combinations of anti-myeloma agents. The increasing abundance of management options makes the decision making complex in different phases of the disease. This book will offer the clinician valuable assistance in the choice and sequencing of therapies, highlighting the need for a personalized approach that reflects the growing recognition that myeloma is not one uniform disease.
The Bethesda Handbook of Clinical Hematology
Written by national recognized experts and senior fellows at leading research institutions, including the National Institutes of Health, and edited by Drs. Griffin P. Rodgers and Neal S. Young, The Bethesda Handbook of Clinical Hematology, 5th Edition, is a concise, comprehensive handbook designed for everyday clinical use. Organized in a quick-reference, portable format, it covers the clinical information you need to know for the diagnosis and treatment all of blood and bone marrow disorders. Readable and practical, the Bethesda Handbook features numerous tables, algorithms, illustrations, and bulleted lists throughout to help bridge the gap between cutting-edge science and everyday clinical practice.
Hematology E-Book
Extensively revised, comprehensive content from leading global contributors ensures that Hematology, 8th Edition, remains your #1 choice for expert guidance in all areas of this rapidly advancing subspecialty. This edition reflects the numerous advances that are redefining the field and dramatically influencing new approaches to diagnosis, treatment, and outcomes. Well-illustrated and clinically focused, it details the basic science and clinical practice of hematology and hematopoietic cellular therapy—covering virtually all aspects of hematology in one definitive resource. - Covers all hematologic disorders, including comprehensive discussions of hematologic malignancies, individualized p...
Novel Agents for Multiple Myeloma
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. It accounts for approximately 1.8% of all hematologic and solid cancers and slightly > 15% of hematologic malignancies in the United States. MM is typically sensitive to different classes of cytotoxic drugs, both as frontline treatment and as treatment for relapsed disease. Unfortunately, even if responses are typically durable, nowadays MM is not considered curable with current approaches. However, MM survival rates have been brilliantly improved thanks to the introduction of novel agents: patients diagnosed after 2010 have had higher rates of novel therapy use and better survival outcomes compared with those of earlier years. Most relevant therapeutic advances over the past decades has been the introduction of novel therapies, such as immune-modifying agents (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib), adopted with or without stem cell transplantation.
CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America, E-Book
In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). - Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. - Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Cancer Consult: Expertise in Clinical Practice, Volume 2
CANCER CONSULT New edition covering the specialties of hematology, oncology and cellular therapy, now in two volumes Cancer Consult: Expertise in Clinical Practice, Volume 2: Neoplastic Hematology & Cellular Therapy, Second Edition includes hundreds of answers to practice-based questions covering the new principles of diagnosis, classification, staging, treatment, and outcomes in the rapidly advancing field of cancer. This textbook series also provides expert guidance in the areas of cancer-related uncertainties and controversies, including experience-based discussions. The book’s smaller size allows for easy access during medical rounds. This volume also includes: Up-to-date clinically re...
Race for a Remedy
How does a mere molecule—a chemical structure—become a drug? And, how do we know that it works safely? In a one-trillion-dollar pharmaceutical industry with high-stakes profits and perils, battles are raging every day to successfully bring a molecule to its birth: an FDA-approved medicine. In Race for a Remedy, internationally renowned expert in cancer treatment and drug development Makhdum Ahmed, MD, takes readers behind the scenes of the fascinating and intense world of cancer drug development. Whether it’s a small molecule, a versatile monoclonal antibody, or the fancy, poster child of cutting-edge cell therapy, modern drugs are built upon a centuries-old solid foundation set by the...
Multiple Myeloma
This book does not provide a comprehensive overview of Multiple Myeloma but a collection of chapters with in-depth information of distinct hot topics in the diagnostic, research and therapeutic fields. The dynamics of testing new drugs for multiple myeloma treatment in clinical trials is breathtaking. Scientific discoveries have uncovered complicated pathogenesis of multiple myeloma; complicated reactions to treatment lead to the creation of super cocktails. Curability of multiple myeloma is a question that is being discussed by the entire professional myeloma world. Improvement of prognosis is a fact which is most important from a patient's perspective. We believe that this book could be of interest to medical professionals specializing in hematooncology, researchers, as well as many others.
Gene and Cellular Immunotherapy for Cancer
Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including...
